PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

DaTscan
Ioflupane ($^{123}$I)
74 MBq/ml solution for injection
Diagnostic Radiopharmaceutical

GE Healthcare Canada Inc,
2300 Meadowvale Boulevard
Mississauga, ON
L5N 5P9

Submission Control No.: 201481

Date of Preparation: December 7, 2017
# Table of Contents

**PART I: HEALTH PROFESSIONAL INFORMATION** ................................................................. 3  
  SUMMARY PRODUCT INFORMATION .............................................................................. 3  
  DESCRIPTION ............................................................................................................... 3  
  INDICATIONS AND CLINICAL USE ........................................................................ 4  
  CONTRAINDICATIONS ............................................................................................ 4  
  WARNINGS AND PRECAUTIONS ............................................................................ 5  
  ADVERSE REACTIONS ............................................................................................. 7  
  DRUG INTERACTIONS ............................................................................................... 7  
  DOSAGE AND ADMINISTRATION .......................................................................... 8  
  RADIATION DOSIMETRY ......................................................................................... 10  
  OVERDOSAGE ........................................................................................................ 11  
  ACTION AND CLINICAL PHARMACOLOGY .......................................................... 12  
  STORAGE AND STABILITY ..................................................................................... 13  
  SPECIAL HANDLING INSTRUCTIONS .................................................................. 13  
  DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... 13  

**PART II: SCIENTIFIC INFORMATION** ............................................................................. 14  
  PHARMACEUTICAL INFORMATION ....................................................................... 14  
  CLINICAL TRIALS ................................................................................................... 15  
  TOXICOLOGY ........................................................................................................... 18  
  REFERENCES .............................................................................................................. 18  

**PATIENT MEDICATION INFORMATION** ...................................................................... 19
DaTscan™
74 MBq/ml solution for injection
Ioflupane (123I)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form /Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous</td>
<td>Solution for Injection 74 MBq/ml at calibration</td>
<td>5% ethanol For a complete listing see Dosage Forms, Composition and Packaging section</td>
</tr>
</tbody>
</table>

DESCRIPTION

Physical Characteristics
The radio-active label in DaTscan is Iodine-123, a cyclotron-produced radionuclide with a half-life of 13.2 hours through proton bombardment of enriched Xenon-124.

<table>
<thead>
<tr>
<th>Radiation</th>
<th>Energy level (keV)</th>
<th>Abundance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma</td>
<td>159</td>
<td>83</td>
</tr>
</tbody>
</table>

External Radiation
The specific gamma ray constant for iodine 123 is 1.6 R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) for 123I is 0.04 cm. The relative transmission of radiation emitted by the radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2 (e.g., the use of 2.16 cm Pb will decrease the external radiation exposure by a factor of about 1,000).

<table>
<thead>
<tr>
<th>Shield Thickness cm of Lead (Pb)</th>
<th>Reduction in In-Air Collision Kerma</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.04</td>
<td>0.5</td>
</tr>
<tr>
<td>0.13</td>
<td>10⁻¹</td>
</tr>
<tr>
<td>0.77</td>
<td>10⁻²</td>
</tr>
<tr>
<td>2.16</td>
<td>10⁻³</td>
</tr>
<tr>
<td>3.67</td>
<td>10⁻⁴</td>
</tr>
</tbody>
</table>

*Calculation based on attenuation and energy-transfer coefficients obtained from National Institute of Standards & Technology Report NISTIR 5632
INDICATIONS AND CLINICAL USE

DaTscan (Ioflupane (\(^{123}\)I) Injection) is a radiopharmaceutical indicated for visualization of functional striatal dopamine transporter using single photon emission computed tomography (SPECT) brain imaging. In adult patients with suspected Parkinsonian Syndromes (PS), DaTscan SPECT imaging may be used as an adjunct to other established evaluations to help differentiate essential tremor from tremor due to PS related to idiopathic Parkinson’s Disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).

DaTscan is unable to discriminate between PD, MSA and PSP.

CONTRAINDICATIONS

- DaTscan is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing of ingredients and of packaging components, see Dosage Forms, Composition and Packaging.
WARNINGS AND PRECAUTIONS

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiopharmaceuticals should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.</td>
</tr>
<tr>
<td>Hypersensitivity reactions have been reported following DaTscan administration. Prior to administration appropriate resuscitation equipment should be available.</td>
</tr>
</tbody>
</table>

**General**
The product should be administered under the supervision of a health professional who is experienced in the use of radiopharmaceuticals. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.

As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.

This radiopharmaceutical should be received, used and administered only by authorized persons in designated clinical settings. Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of the local competent official organizations.

DaTscan contains alcohol (ethanol) 5% by volume. Each dose contains up to 197 mg alcohol which is the amount contained in approximately 5 ml of beer or 2 ml of wine. The alcohol content should be taken into consideration when DaTscan is to be administered to patients who have alcoholism, liver disease, or epilepsy, and also in patients who are pregnant or breastfeeding.

**Hypersensitivity Reactions**
Hypersensitivity reactions have been reported following DaTscan administration. Prior to administration, the patient should be questioned for a history of reactions to iodine, an iodine-containing contrast agent or other products containing iodine. If the patient is known or strongly suspected to have hypersensitivity to any of the above, the decision to administer DaTscan should be based upon an assessment of the expected benefits compared to the potential hypersensitivity risks. Anaphylactic and hypersensitivity treatment measures and resuscitative equipment (e.g., endotracheal tube and ventilator) should be available prior to DaTscan administration. If hypersensitivity reactions occur, DaTscan administration must be discontinued immediately.

**Thyroid Accumulation of I-123**
The DaTscan injection may contain up to 6% of free iodide (iodine 123). Accumulation of radiiodine in the thyroid gland may result in long term risk for thyroid neoplasia. To decrease thyroid accumulation of iodine 123, administer a thyroid blocking agent before administration of DaTscan [see Dosage and Administration]. Avoid the use of Potassium Iodide Oral Solution or Lugol’s Solution in patients who are sensitive to such products.
Risks with Concomitant Medication Withdrawal
Many medications have the potential to interfere with DaTscan imaging, and may result in unreliable imaging results. Review of the patient’s medications in advance of the scheduled DaTscan imaging procedure is required to determine whether any medications should be withdrawn prior to DaTscan dosing, and whether the withdrawal can be accomplished safely. DaTscan imaging should not be performed if discontinuation of these medications would involve risks which outweigh the value of DaTscan imaging. (See Drug-Drug Interactions).

Contamination
The following measures should be taken for up to 12 hours after receiving the radiopharmaceutical product: Toilet should be used instead of urinal. Toilet should be flushed several times after use. If blood or urine gets onto clothing such clothing should be washed separately or stored for 1 to 2 weeks to allow for radioactive decay.

Special precautions such as bladder catheterization should be taken following administration to incontinent patients to minimize the risk of radioactive contamination of clothing, bed linen and the patient’s environment.

Special Populations

Paediatric Population
The safety and efficacy of DaTscan in children aged 0 to 18 years has not been established, therefore DaTscan is not recommended in children.

Women of Childbearing Potential
Where it is necessary to administer radioactive medicinal products to women of childbearing potential, information should always be sought about pregnancy. Any woman who has missed a period should be assumed pregnant until proven otherwise. Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving satisfactory imaging. Alternative techniques which do not involve ionizing radiation should be considered.

Ideally examinations using radiopharmaceuticals, especially those elective in nature of women of childbearing capability should be performed during the first ten days following the onset of menses.

Pregnant Women
Since adequate reproduction studies have not been performed in animals to determine whether this drug affects fertility in males or females, has teratogenic potential, or has other adverse reactions on the fetus, this radiopharmaceutical preparation should not be administered to pregnant women unless it is considered that the benefits to be gained outweigh the potential hazards to the fetus.

Nursing Women
Before administering a radioactive medicinal product to a mother who is breastfeeding, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breastfeeding and as to whether the most appropriate choice of radiopharmaceutical has been made, bearing in mind the secretion of activity in breast milk. It is not known whether ioflupane (123I) is secreted in human milk, therefore, if administration is considered necessary, breast-feeding should be interrupted for 3 days and substituted by
formula feeding. During this time, breast milk should be expressed at regular intervals and the expressed feeds should be discarded.

**Renal and Hepatic Impairment**

Formal studies have not been carried out in patients with significant renal or hepatic impairment. In the absence of data, DaTscan is not recommended in cases of moderate to severe renal or hepatic impairment.

**ADVERSE REACTIONS**

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The data from clinical studies reflect exposure to DaTscan in 942 subjects with a mean age of 66 years (range 25 to 90 years). Among these subjects, 42% were women and 99% Caucasian. In clinical trials, no serious adverse reactions were reported.

**Adverse Drug Reaction Overview**

No serious adverse effects related to DaTscan administration have been reported in eight clinical trials (942 patients) that were used to assess the clinical safety of DaTscan.

**Clinical Trial Adverse Drug Reactions**

Adverse events (AEs) that were commonly reported (≥2%) in these clinical trials were headache, nausea and dizziness. Not all cases were considered related to DaTscan administration. AEs considered by the investigator to be at least possibly related to DaTscan, were less commonly reported. These included vertigo, increased appetite, dry mouth, formication, and dysgeusia. Most of these AEs were mild and none were assessed to be adverse drug reactions. Injection site pain was uncommonly reported.

**Post-Market Adverse Drug Reactions**

Reports of serious and nonserious hypersensitivity or associated manifestations (e.g., erythema, generalized pruritus, dyspnea, oedema, skin lesion, and skin discoloration), as well as reports of injection site pain, headache, dizziness, formication (paresthesia), dysgeusia, nausea and dry mouth have been received from post-marketing surveillance.

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 4.35 mSv when the maximal recommended activity of 185 MBq is administered, these adverse events are expected to occur with a low probability.

For each patient, exposure to ionising radiation must be justifiable on the basis of likely benefit and the injected activity should be kept to a minimum but sufficient to obtain the intended diagnostic signal.

**DRUG INTERACTIONS**

No GE Healthcare sponsored drug interaction studies have been carried out in humans.

Ioflupane binds to the dopamine transporter. Drugs that bind to the dopamine transporter with high affinity can interfere with DaTscan binding, therefore may affect the images
obtained following DaTscan administration (see Table 3).

Table 3  
Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Drug</th>
<th>Source of Evidence</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>T</td>
<td>Potential reduction of ioflupane striatal binding</td>
<td>Consider temporary discontinuation of use(^2,3)</td>
</tr>
<tr>
<td>Benzatropine</td>
<td>T</td>
<td>Potential reduction of ioflupane striatal binding</td>
<td>Consider temporary discontinuation of use(^2)</td>
</tr>
<tr>
<td>Bupropion</td>
<td>T</td>
<td>Potential reduction of ioflupane striatal binding</td>
<td>Consider temporary discontinuation of use(^2)</td>
</tr>
<tr>
<td>Cocaine</td>
<td>T</td>
<td>Potential reduction of ioflupane striatal binding</td>
<td>Consider temporary discontinuation of use(^2)</td>
</tr>
<tr>
<td>Mazindol</td>
<td>T</td>
<td>Potential reduction of ioflupane striatal binding</td>
<td>Consider temporary discontinuation of use(^2)</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>T, CT</td>
<td>Reduction of ioflupane striatal binding ratios</td>
<td>Consider temporary discontinuation of use(^4)</td>
</tr>
<tr>
<td>Phentermine</td>
<td>T</td>
<td>Not specified</td>
<td>Consider temporary discontinuation of use(^4)</td>
</tr>
<tr>
<td>Sertraline</td>
<td>T</td>
<td>Not specified</td>
<td>Consider temporary discontinuation of use(^4)</td>
</tr>
</tbody>
</table>

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

Medicines shown during clinical trials not to interfere with DaTscan imaging include amantadine, trihexyphenidyl, budipine, levodopa, metoprolol, primidone, propranolol and selegiline. The impact of dopamine agonists and antagonists has not been established.

Interactions with food, herbs, and laboratory tests have not been established.

**DOSAGE AND ADMINISTRATION**

**Patient Preparation**

Prior to administration, question the patient for:

- a history of prior reactions to iodine, an iodine-containing contrast agent or other products containing iodine,
- prior or current medications,
- history of head trauma, stroke, psychiatric illness, epilepsy, or tumor, and
- the patient’s ability to lie still for approximately 30 to 45 minutes.

Patients should have discontinued all medications that could interfere with uptake of DaTscan. (see **WARNINGS AND PRECAUTIONS, Risks with Concomitant Medications Withdrawal, and DRUG INTERACTIONS**).

**Thyroid Blockade**

To reduce exposure of the thyroid to free \(^{123}\)I, administer a single 400-mg dose of potassium perchlorate or a single dose of potassium iodide oral solution or Lugol’s solution (equivalent to 100 mg iodide) at least 1 hour before the tracer injection.
**Dosage**
Recommended dose is 111 to 185 MBq administered intravenously. Do not exceed 185 MBq and do not use when the activity is below 110 MBq. In the event of overdose, refer to *Overdosage section.*

**Administration**
Prior to administration appropriate resuscitation equipment should be available.

DaTscan is a solution for intravenous injection. It should be used without dilution.

Aseptic technique using sterile syringes and needles should be used.

The patient dose should be measured by a suitable radioactivity calibration system prior to administration.

To minimize the potential for pain at the injection site during administration, a slow intravenous injection (not less than 15 to 20 seconds) via an arm vein is recommended.

Prior to imaging, patients should be encouraged to drink large volumes of fluids and to void frequently prior to imaging, to facilitate excretion of DaTscan.

**Image Acquisition and Interpretation**
Images may be acquired using either multi-headed gamma cameras or multi-detector single slice systems. Each gamma camera system must be capable of Single-photon emission computed tomography (SPECT) acquisition and reconstruction to produce transverse slices including a clear visualization of the striatum (head of caudate nucleus and putamen). The single slice detector systems must also be capable of imaging these structures (5-cm minimum detector width to capture the entire striatum in a single acquisition).

SPECT imaging should take place between three and six hours post-injection. Images should be acquired using a gamma camera fitted with a high-resolution collimator and calibrated using the 159 keV photopeak and a ± 10% energy window. Angular sampling should preferably be not less than 120 views over 360 degrees. For high-resolution collimators the radius of rotation should be consistent and set as small as possible (typically 11 to 15 cm). Experimental studies with a striatal phantom suggest that optimal images are obtained with matrix size and zoom factors selected to give a pixel size of 3.5 to 4.5 mm for those systems currently in use. A minimum of 1500k counts should be collected for optimal images.

**Image Interpretation**
DaTscan images are interpreted visually or in combination with semiquantification, based upon the appearance of the striata.

Reconstructed pixel size should be between 3.5 and 4.5 mm with slices 1 pixel thick. Optimum presentation of the reconstructed images for visual interpretation is transaxial slices parallel to the anterior commissure-posterior commissure (AC-PC) line. Determination of whether an image is normal or abnormal is made by assessing the extent (as indicated by shape) and intensity of the striatal signal. Image interpretation does not involve integration of the striatal image appearance with clinical signs and/or symptoms.

**Normal:**
In transaxial images, normal images of the striatal binding are characterized by two symmetric comma- or crescent-shaped focal regions of activity mirrored about the median plane. Striatal activity is distinct, relative to surrounding brain tissue (Figure 1).
Abnormal:
Abnormal DaTscan images fall into at least one of the following three categories (all are considered abnormal).

- **Activity is asymmetric, e.g. activity in the region of the putamen of one hemisphere is absent or greatly reduced with respect to the other. Activity is still visible in the caudate nuclei of both hemispheres resulting in a comma or crescent shape in one and a circular or oval focus in the other. There may be reduced activity between at least one striatum and surrounding tissues (Figure 2).**

- **Activity is absent in the putamen of both hemispheres and confined to the caudate nuclei. Activity is relatively symmetric and forms two roughly circular or oval foci. Activity of one or both is generally reduced (Figure 3).**

- **Activity is absent in the putamen of both hemispheres and greatly reduced in one or both caudate nuclei. Activity of the striata with respect to the background is reduced (Figure 4).**

**Figure 1**

**Figure 2**

**Figure 3**

**Figure 4**

**Semiquantification**

Semiquantification is defined as the ratio of activity in a structure of interest to activity in a reference region. For semiquantification of $^{123}$I-ioflupane DaT SPECT, binding ratios are calculated by comparing activity in the striatum with activity in an area of low DaT concentration (usually the occipital area). Good results for diagnosis based solely on semiquantification have been reported. Semiquantification may yield more objective results and may be of benefit to the inexperienced reader. Semiquantitative data must be compared with an established set of reference values, preferably age-matched.

**RADIATION DOSIMETRY**

The estimated absorbed radiation doses are listed below [Table 4]. The biokinetic model for ioflupane ($^{123}$I) adopted here assumes initial uptake of 31% of the administered activity in the
liver, 11% in the lungs, and 4% in the brain. The rest is assumed to be distributed uniformly in the remaining organs and tissues. For all organs and tissues, 80% is assumed to be excreted with a biological half-time of 58 h, and 20% with a half-time of 1.6 h. It is further assumed that 60% of the injected activity is excreted to the urine, and 40% is excreted to the gastrointestinal tract for all organs and tissues. Activity in the liver is excreted according to the Publication 53 gallbladder model (ICRP, 1987), where 30% is eliminated via the gallbladder and the remainder passes directly into the small intestine.

Table 4 The Estimated Absorbed Radiation Doses for ioflupane (123I)

<table>
<thead>
<tr>
<th>ORGAN</th>
<th>Absorbed radiation dose µGy/MBq</th>
<th>Absorbed radiation dose rad/mCi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenals</td>
<td>17.0</td>
<td>0.063</td>
</tr>
<tr>
<td>Bone surfaces</td>
<td>15.0</td>
<td>0.056</td>
</tr>
<tr>
<td>Brain</td>
<td>16.0</td>
<td>0.059</td>
</tr>
<tr>
<td>Breast</td>
<td>7.3</td>
<td>0.027</td>
</tr>
<tr>
<td>Gallbladder wall</td>
<td>44.0</td>
<td>0.163</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach wall</td>
<td>12.0</td>
<td>0.044</td>
</tr>
<tr>
<td>Small intestine wall</td>
<td>26.0</td>
<td>0.096</td>
</tr>
<tr>
<td>Colon wall</td>
<td>59.0</td>
<td>0.218</td>
</tr>
<tr>
<td>(Upper large intestine wall</td>
<td>57.0</td>
<td>0.211</td>
</tr>
<tr>
<td>(Lower large intestine wall</td>
<td>62.0</td>
<td>0.229</td>
</tr>
<tr>
<td>Heart wall</td>
<td>32.0</td>
<td>0.118</td>
</tr>
<tr>
<td>Kidneys</td>
<td>13.0</td>
<td>0.048</td>
</tr>
<tr>
<td>Liver</td>
<td>85.0</td>
<td>0.315</td>
</tr>
<tr>
<td>Lungs</td>
<td>42.0</td>
<td>0.155</td>
</tr>
<tr>
<td>Muscles</td>
<td>8.9</td>
<td>0.033</td>
</tr>
<tr>
<td>Esophagus</td>
<td>9.4</td>
<td>0.035</td>
</tr>
<tr>
<td>Ovaries</td>
<td>18.0</td>
<td>0.067</td>
</tr>
<tr>
<td>Pancreas</td>
<td>17.0</td>
<td>0.063</td>
</tr>
<tr>
<td>Red marrow</td>
<td>9.3</td>
<td>0.034</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>41.0</td>
<td>0.152</td>
</tr>
<tr>
<td>Skin</td>
<td>5.2</td>
<td>0.019</td>
</tr>
<tr>
<td>Spleen</td>
<td>26.0</td>
<td>0.096</td>
</tr>
<tr>
<td>Testes</td>
<td>6.3</td>
<td>0.023</td>
</tr>
<tr>
<td>Thymus</td>
<td>9.4</td>
<td>0.035</td>
</tr>
<tr>
<td>Thyroid</td>
<td>6.7</td>
<td>0.025</td>
</tr>
<tr>
<td>Urinary bladder wall</td>
<td>35.0</td>
<td>0.130</td>
</tr>
<tr>
<td>Uterus</td>
<td>14.0</td>
<td>0.052</td>
</tr>
<tr>
<td>Remaining organs</td>
<td>10.0</td>
<td>0.037</td>
</tr>
<tr>
<td>Effective dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25.0 µSv/MBq</td>
<td></td>
<td>925 µSv/mCi</td>
</tr>
</tbody>
</table>


The effective dose ($E$) resulting from administration of 185 MBq of DaTscan injection is estimated at 4.63 mSv. The above data are valid in normal pharmacokinetic behavior. When renal or hepatic function is impaired, the effective dose and the radiation dose delivered to organs might be increased.

OVERDOSAGE

In cases of overdose of radioactivity, frequent micturition and defecation should be encouraged to minimise radiation dosage to the patient. Care should be taken to avoid contamination from the radioactivity eliminated by the patient using such methods.

For management of a suspected drug overdose, contact your regional Poison Control Centre
ACTION AND CLINICAL PHARMACOLOGY

DaTscan is a radiolabeled tropane compound with high affinity for the dopamine transporter (DaT). The DaT is present exclusively on dopamine synthesizing neurons and DaT can therefore be considered a specific marker of these neurons in the central nervous system. Because DaT distribution in the CNS coincides with dopaminergic innervation, tropane analogues with high DaT binding affinity have been developed for use in neuroimaging as *in vivo* markers of functional dopaminergic systems. Biological studies *in vitro* and *in vivo* have demonstrated that when radiolabelled with the gamma-emitting isotope iodine-123, ioflupane has the appropriate characteristics to enable SPECT visualization of regions of the brain with a high expression of the DaT.

**Mechanism of Action**

DaTscan is a diagnostic radiopharmaceutical containing ioflupane ($^{123}$I), for detecting loss of functional nigrostriatal dopaminergic neurons by SPECT imaging. It is intended to detect or exclude a substantial (>60%) loss of nigrostriatal dopaminergic neurons in patients with the signs and symptoms of movement disorders. The mechanism is that the active component in DaTscan, ioflupane ($^{123}$I), distributes to the brain and preferentially binds to the DaT located predominantly on the nigrostriatal dopaminergic neurons. In healthy humans, this results in visualization of the striata as two “comma”- or “half-moon”-shaped areas of brightness on SPECT imaging. However, loss of the nigrostriatal dopaminergic neurons (e.g., in PD or DLB) results in loss of the DaT associated with those neurons. This results in the absence of signal where it normally would be expected.

**Pharmacodynamics**

In the absence of receptor agonist activity and because of the tracer amounts required for such diagnostic procedures (approximately 0.3 mcg), there is no possibility of pharmacodynamic effects. Taking into account the percent of ioflupane ($^{123}$I) distributed to the brain (9%), and the total number of DaT in the human striatum (approximately 16 nmol) the maximum dose of ioflupane is estimated to occupy approximately 0.01% of the total DaT available. In comparison, the DaT occupancy required by cocaine to induce any psychotropic effects in humans is approximately 45% of the total DaT in the striatum [Volkow et al. 1997].

**Absorption**

The pharmacokinetics of ioflupane ($^{123}$I) has been studied in 12 healthy adults. The biodistribution of ioflupane ($^{123}$I) may not be the same in older subjects with Parkinsonian syndromes. Because administration is intravenous, absorption is complete and ioflupane ($^{123}$I) is completely bioavailable.

**Distribution**

Ioflupane ($^{123}$I) is cleared rapidly from the blood after intravenous injection; only 5% of the administered activity remains in whole blood at 5 minutes post-injection.

**Organ Uptake**

Uptake in the brain is rapid, reaching about 7% of injected radioactivity at 10 minutes post-injection and decreasing to 3% after 5 hours; striatal activity is relatively constant between 3 and 6 hours post-injection. About 30% of the whole brain radioactivity is attributed to striatal uptake.
The highest levels of radioactivity were measured in the lungs, liver, and brain. The lung showed the widest (inter-subject) variation in initial uptake and in residence times.

**Metabolism**
Analysis of metabolites in human plasma has been reported. Since none of the metabolites is expected to cross the blood brain barrier they are considered unlikely to alter the diagnostic efficacy of DaTscan.

**Excretion**
At 48 hours post-injection, approximately 60% of the injected radioactivity is excreted in the urine, with fecal excretion calculated at approximately 14%.

**STORAGE AND STABILITY**
The test product should be stored at room temperature (20° to 25°C) in a lead shielded container. Do not freeze.

Shelf-life of the product: 7 hours from the reference time for the 2.5mL vial and 20 hours from the reference time for the 5.0mL vial.

**SPECIAL HANDLING INSTRUCTIONS**
As in the use of any other radioactive material, care should be taken to minimize radiation exposure to patients consistent with proper patient management, and to minimize radiation exposure to occupational workers.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**
DaTscan is a sterile solution for intravenous administration containing ioflupane ($^{123}$I) 74 MBq/mL (2 mCi/ml) at reference time (0.07 to 0.13 mcg/ml of ioflupane).

- Each 2.5-ml single-dose vial contains 185 MBq ioflupane ($^{123}$I) (specific activity range 2.5 to 4.5 x 10$^{14}$ Bq/mmol) at reference time.
- Each 5-ml single-dose vial contains 370 MBq ioflupane ($^{123}$I) (specific activity range 2.5 to 4.5 x 10$^{14}$ Bq/mmol) at reference time.

The product also contains acetic acid, sodium acetate, 5% v/v ethanol and water for injection.

The product is supplied as 2.5 or 5 ml solution in a single colourless 10-ml glass vial sealed with a rubber closure and metal overseal.
**PART II: SCIENTIFIC INFORMATION**

**PHARMACEUTICAL INFORMATION**

**Drug Substance**

<table>
<thead>
<tr>
<th>International Non-Proprietary Name (INN)</th>
<th>Ioflupane ((^{123})I)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemical name</strong></td>
<td>Methyl (1R-2S-3S-5S)-8-(3-fluoropropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1] octane-2-carboxylate</td>
</tr>
<tr>
<td><strong>Trivial Chemical Name</strong></td>
<td>N-(\omega)-fluoropropyl-2(\beta)-carbomethoxy-3(\beta) -(4-(^{123})Iiodophenyl)nortropane</td>
</tr>
<tr>
<td><strong>Structure</strong></td>
<td><img src="image" alt="structure" /></td>
</tr>
<tr>
<td><strong>Molecular Formula</strong></td>
<td>C(<em>{18})H(</em>{23})F(^{123})INO</td>
</tr>
<tr>
<td><strong>Relative Molecular Mass</strong></td>
<td>427.29 (for the iodine-123 compound)</td>
</tr>
<tr>
<td><strong>Chirality</strong></td>
<td>The molecule is optically active. The route of manufacture ensures that only the 2(\beta),3(\beta)- isomer is present in the active substance</td>
</tr>
</tbody>
</table>

**Product Characteristics**

Ioflupane (\(^{123}\)I) injection is a clear, colorless aqueous solution with a pH of 4.0 to 6.0. Each vial contains 185 MBq ioflupane (\(^{123}\)I) at reference time in 2.5 ml of solution. The 5.0-ml presentation contains 370 MBq at reference.

Radiochemical purity: Not less than 96% ioflupane (\(^{123}\)I) at release, not less than 94 % at expiry.

Not more than 4% \(^{123}\)Iiodide at release, not more than 6% at expiry.

Not more than 2% \(^{123}\)FP-CIT acid at release and expiry.

DaTscan is carrier-added.
CLINICAL TRIALS

Study Demographics and Trial Design

Table 5  Summary of Patient Demographics for Pivotal Clinical Trials in Parkinson’s Syndrome

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration of treatment</th>
<th>Study subjects (n = number)</th>
<th>Mean age (Range)/Gender M/F</th>
<th>Race (%)/H&amp;Y Staging</th>
</tr>
</thead>
<tbody>
<tr>
<td>DP008-003 [DP008-003 CREP US]</td>
<td>Phase 3, Multicenter, Comparator-group, Open-label, Non-controlled, Non-randomized, No control</td>
<td>111 to 185 MBq (3 to 5 mCi), iv injection, 1 day</td>
<td>Subjects diagnosed with PD, MSA, PSP or ET aged 40-80 years; healthy volunteers aged 50-80 years. (n = 224)</td>
<td>63 years (40 – 80) M/F:137/87</td>
<td>Race: Caucasian: 98% H&amp;Y: Stage 1: 15% Stage 2: 21% Stage 3: 13% Stage 4: 11%</td>
</tr>
<tr>
<td>PDT03004 (aka PDT304) [PDT304 CREP US]</td>
<td>Phase 3, Multicenter, Open-label, Non-comparative, Non-randomized, Repeat administration, No control</td>
<td>111 to 185 MBq (3 to 5 mCi), iv injection, 36 months</td>
<td>Subjects 30-90 years old with early PD or with other causes of tremor (mainly ET); healthy volunteers. (n = 179)</td>
<td>63 years (34 – 86) M/F: 102/77</td>
<td>Race: Caucasian: 100% H&amp;Y: mean 1.5 (range: 1 - 3)</td>
</tr>
</tbody>
</table>

ET = essential tremor; iv = intravenous; MSA = multiple system atrophy; PD = Parkinson’s disease; PS = Parkinsonian syndrome; PSP = progressive supranuclear palsy

Study Results

Study DP008-003 was a pivotal, multicenter, Phase 3 study that evaluated the diagnostic performance of DaTscan images in patients diagnosed with movement disorders and in healthy volunteers. Patients aged 40 to 80 with a clinically established diagnosis of PD, MSA, PSP or ET and healthy volunteers aged 50 to 80 were enrolled into the study.

The primary efficacy endpoint was the diagnostic efficacy of DaTscan SPECT image assessment by institutional reader. Secondary endpoints were the diagnostic efficacy of DaTscan SPECT image visual assessment by blinded consensus read and semiquantitative Region of Interest (ROI) analysis of SPECT images.

Each subject received a single iv injection of 111 to 185 MBq (3 to 5 mCi) DaTscan followed 3 to 6 hours later by SPECT imaging. In addition, a Blinded Image Evaluation (BIE) was performed on images that had been processed to a uniform color scale and format, blinded, and randomized. In both image evaluations, images were classified as normal or abnormal based on the appearance of the striata. The BIE was performed by a panel consisting of 5 of the study’s 13 investigators; each of these 5 readers independently viewed and classified all blinded images. “Consensus” (majority) blinded image interpretations were derived from the individual blinded readers’ interpretations for each subject (e.g., if 3 of 5 readers called the image abnormal, then the “consensus” [majority] assessment was abnormal). As an additional analysis in the original study protocol, a semi-quantitative assessment was performed by the core imaging laboratory based on region-of-interest (ROI) analysis.

Each image interpretation was compared to the SOT (categorization of patient status at study entry as SDD present or absent), and classified as TN, TP, FN, or FP and the classification counts were used to determine sensitivity and specificity as described above.
The per-reader sensitivity of the blinded visual assessment for the intent-to-diagnose (ITD) population in identifying a SDD ranged from 92.4% to 96.8%, and specificity ranged from 80.6% to 96.8%. Inter-reader agreement (Cohen’s kappa) ranged from 0.81 to 0.95. The results of the semi-quantitative ROI analysis were consistent with the visual image assessments and with the known pathology of these disorders.

Table 6  Summary of Sensitivity and Specificity by SOT Diagnosis

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity (95 % CI) (% subjects with an abnormal DaTSCAN image among patients with PS)</th>
<th>Specificity (95 % CI) (% subjects with a normal DaTSCAN image among patients with non-PS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reader A, n = 220</td>
<td>93 (88, 97)</td>
<td>94 (84, 98)</td>
</tr>
<tr>
<td>Reader B, n = 220</td>
<td>97 (93, 99)</td>
<td>81 (69, 90)</td>
</tr>
<tr>
<td>Reader C, n = 220</td>
<td>96 (92, 99)</td>
<td>92 (82, 97)</td>
</tr>
<tr>
<td>Reader D, n = 220</td>
<td>92 (87, 96)</td>
<td>97 (89, 100)</td>
</tr>
<tr>
<td>Reader E, n = 220</td>
<td>94 (90, 97)</td>
<td>92 (82, 97)</td>
</tr>
</tbody>
</table>

**Study PDT03004 (aka PDT304)** was a pivotal, multicenter, Phase 3 study that evaluated the diagnostic performance of DaTscan images in differentiating between subjects with early symptoms and signs of movement disorders, specifically Parkinsonism (SDD present), other causes of tremor (mainly ET, no SDD), and healthy volunteers (no SDD). Key inclusions were age 30 to 90 years, inclusive, UPDRS part III score of 16 or less and subjects either with cardinal features of Parkinsonism and fulfilling UK Brain Bank criteria or with any single feature of Parkinsonism but the diagnosis was not clear. The study excluded patients with history and evidence of stroke, depression, MSA, PSP and dementia.

There were 202 subjects enrolled in the study, including 3 healthy volunteers. A total of 99 subjects underwent DaTscan SPECT imaging at months 0, 18, and 36 and were evaluated against the Standard of Truth (SOT). At each time point, SPECT imaging was conducted 3 to 6 hours following a single iv injection of 111 to 185 MBq (3 to 5 mCi) of DaTscan. Scans were read independently by 3 blinded readers for the main efficacy analysis and on-site for secondary analyses.

Patients were videotaped undergoing neurological examination at 18 and 36 months. The 36-month videos were used as the SOT; they were reviewed by 2 movement disorder specialists (MDS), who each decided on the SOT diagnosis. If the 2 diagnoses did not agree, the 2 MDS’ discussed the video and reached consensus on the SOT diagnosis.

Each DaTscan image interpretation was compared to the corresponding SOT diagnosis and classified as a TP, TN, FP, or FN, and the classification counts were used to determine sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV).

The primary endpoint was diagnostic efficacy of DaTscan SPECT images taken at month 0 compared with clinical diagnosis at month 36. The secondary endpoint was diagnostic efficacy of DaTscan SPECT images taken at month 0 compared with expert diagnosis at other time points.
The sensitivity and specificity of the blinded visual interpretations of the DaTscan SPECT images acquired at baseline (0 months), month 18 and month 36 for the ITD population ranged are presented in Table 7. The results thus remained stable over the course of the study. Pairwise inter-reader agreement (Cohen’s kappa) among the blinded readers ranged from 0.98 to 1.00.

Table 7  Summary of Sensitivity and Specificity by SOT Diagnosis

<table>
<thead>
<tr>
<th>DaTscan imaging at Baseline</th>
<th>Sensitivity (95% CI) (% subjects with an abnormal DaTSCAN image among patients with PS)</th>
<th>Specificity (95% CI) (% subjects with a normal DaTSCAN image among patients with non-PS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reader A, n = 102</td>
<td>78% (66, 87)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>Reader B, n = 99</td>
<td>78% (66, 87)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>Reader C, n = 101</td>
<td>79% (67, 88)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>DaTscan imaging at Month 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reader A, n = 102</td>
<td>78 (66, 87)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>Reader B, n = 99</td>
<td>78 (66, 87)</td>
<td>94 (79, 99)</td>
</tr>
<tr>
<td>Reader C, n = 101</td>
<td>82 (71, 90)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>DaTscan Imaging at Month 36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reader A, n = 102</td>
<td>75 (63, 85)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>Reader B, n = 99</td>
<td>77 (65, 87)</td>
<td>97 (83, 100)</td>
</tr>
<tr>
<td>Reader C, n = 101</td>
<td>78 (66, 87)</td>
<td>97 (83, 100)</td>
</tr>
</tbody>
</table>
TOXICOLOGY

Acute Toxicity:
Acute toxicity studies of ioflupane (the active ingredient of DaTscan) showed that the highest doses that caused neither deaths nor signs of toxicity were 1 mg/kg in rats, 0.06 mg/kg in rabbits, 0.3 mg/kg in dogs and 0.1 mg/kg in cynomolgus monkeys. When adjusted for surface area, these doses are respectively approximately 27000, 3200, 30000 and 5500 times the maximum human equivalent dose of ioflupane that could be administered by the 2.5-mL formulation of DaTscan (for the 5-mL formulation, divide the value by two).

Repeat-Dose Studies:
In 14-day repeat-dose studies, no evidence of toxicity was observed in rats or rabbits following daily doses of ioflupane of up to 0.6 mg/kg or in dogs up to doses of 1 mcg/kg (between 100 and 32000 times the maximum human single dose based on the 2.5-mL formulation). Behavioural effects due to pharmacological activity were observed in these studies.

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether DaTscan affects fertility in males or females.

As with other radiopharmaceuticals which distribute intracellularly, there may be increased risk of chromosome damage from Auger electrons if nuclear uptake occurs.

Genotoxicity
Ioflupane showed no evidence of mutagenic potential in in vitro or in vivo mutagenicity studies.

REFERENCES

1. [Volkow et al. 1997]

2. [Booij and Kemp 2008]

3. [Nycomed Amersham Report DP008R/066, 1998]
Nycomed Amersham Report DP008R/066, 1998

4. [ICRP 2015]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

DaTscan

74 MBq/ml solution for injection
Ioflupane ($^{123}$I)

Read this carefully before you receive DaTscan. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about DaTscan.

**Serious Warnings and Precautions**

Serious allergic reactions have occurred in some patients who received DaTscan. Tell your doctor if you have had allergic reactions to other diagnostic agents or iodine-containing products.

**What is DaTscan used for?**

DaTscan is a radioactive diagnostic agent which is used with a special camera to take pictures of the brain.

In adult patients who have symptoms of Parkinsonian Syndromes (such as Parkinson’s disease), DaTscan is used along with other diagnostic tests to give the doctor more information about their condition.

**How does DaTscan work?**

When DaTscan is injected into a vein, it is carried around the body in the blood. It collects in a small area of your brain. The small amount of radioactivity can be detected from outside the body using a special camera that will take a picture, or scan, of your brain.

The scan will show if there are any changes in this area of your brain and will give your doctor more information about your condition.

When DaTscan is used, you are exposed to small amounts of radioactivity. This exposure is less than some other types of X-ray investigation. Your doctor will always consider the possible risks and benefits of DaTscan.

**What are the ingredients in DaTscan?**

- The active substance is ioflupane ($^{123}$I).
- The other ingredients are acetic acid, sodium acetate, ethanol and water for injections.

**DaTscan comes in the following dosage forms:**

DaTscan is available as a 2.5- or 5-ml solution containing 185 MBq ioflupane ($^{123}$I) or 370 MBq ioflupane ($^{123}$I), respectively.
Do not use DaTscan if:
- you are allergic to ioflupane or any of the other ingredients of DaTscan

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DaTscan. Talk about any health conditions or problems you may have, including:
- Are breast-feeding, your doctor may delay the use of DaTscan, or ask you to stop breastfeeding. It is not known whether ioflupane(123I) is passed into breast milk. As a precaution, you should not breast-feed your child for 3 days after DaTscan is given. Instead use formula feed for your child. Express your breast milk regularly and throw away any breast milk you have expressed. You will need to continue to do this for 3 days, until the radioactivity is no longer in your body.
- Have moderate or severe problems with your kidneys or liver

Other warnings you should know about:
DaTscan contains alcohol (ethanol) 5 % by volume. Each dose contains up to 197 mg alcohol which is the amount contained in approximately 5 ml of beer or 2 ml of wine. The alcohol content of DaTscan may be harmful to patients who have alcoholism, liver disease, or epilepsy, and also in patients who are pregnant or breastfeeding. If you have concerns in this regard, discuss with your Doctor.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Some drugs may reduce the quality of the picture obtained with DaTscan. If you are taking any of the drugs listed below or any other drugs that may interfere with DaTscan, you may be asked to stop taking them for a short time before you receive DaTscan. Ask your doctor whether you can safely stop taking your medications.

The following may interfere with DaTscan:
- bupropion
- benztropine
- mazindol
- sertraline
- methylphenidate
- phentermine
- amphetamine
- cocaine

How to take DaTscan:

DaTscan will be given to you by a healthcare professional who is experienced in the use of radiopharmaceuticals. They should tell you anything you need to do for the safe use of this medicine. Your doctor will decide the dose that is best for you.

Before you receive DaTscan, your doctor will ask you to take some tablets or liquid that contain iodine, to help prevent radioactivity from building up in your thyroid gland. It is important that you take the tablets or liquid as the doctor tells you.

DaTscan is given to you as an injection, usually into a vein in your arm. Pictures of your brain will be taken 3 to 6 hours after the injection of DaTscan.
You should drink large glasses of water before and after you get your injection of DaTscan, and urinate frequently in the hours after your injection to reduce the amount of radioactivity in your bladder.

**What are possible side effects from using DaTscan?**
Like all medicines, DaTscan can cause side effects, although not everybody gets them.

These are not all the possible side effects you may feel when taking DaTscan. If you experience any side effects not listed here, contact your healthcare professional. Please also see *Warnings and Precautions*.

**Common:** may affect up to 1 in 10 people
- Headache
- Dizziness
- Nausea

**Uncommon:** may affect up to 1 in 100 people. You may experience the following uncommon side effects:
- Increased appetite
- Taste disturbance
- Dry mouth
- Vertigo
- A sensation like insects crawling over your skin (formication)
- Intense pain on injection. This has been reported among patients receiving DaTscan into a small vein

**Not known:** frequency cannot be estimated from the available data
- Allergic reaction (hypersensitivity)

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
<th>Talk to your health professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom/effect</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Allergic reaction</td>
<td>✗</td>
<td>Yes</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
**Reporting Side Effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

**3 ways to report:**

- Online at [MedEffect](#);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program  
    Health Canada, Postal Locator 0701E  
    Ottawa, ON  
    K1A 0K9

   Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](#).

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

---

**If you want more information about DaTscan**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website; or by calling 1-800-387-7146

This leaflet was prepared by GE Healthcare

Last Revised December 7, 2017